Changing society guidelines and insurance policies have resulted in more interest in CCTA. To help your CCTA program expand, one expert told Cardiovascular Business, it is important to remember the close relationship between cardiology and radiology. 

Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.

The co-chairs of the American Society of Echocardiography's 2025 meeting wanted to "highlight the unique value of being in person." They looked back at the three-day event with Cardiovascular Business.

“Multimodality imaging in cardio-oncology is something many of us in the field are truly excited about," Daniel Addison, MD, told Cardiovascular Business. He noted that modalities other than echocardiography are starting to play a much larger role in the treatment of these patients.

As the United States continues to move toward quality-based care, ACOs need to rethink the way they attribute care to cardiologists and other members of the heart team. 

"PET has changed the practice of nuclear medicine in general and I think it is going to revitalize the practice of cardiology,"  Marcelo Di Carli, MD, told Cardiovascular Business. He noted that more practices seem interested in implementing PET than ever before.

Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away.

Researchers, for example, could improve disparities by performing their tests on more diverse groups of patients. Daniel Addison, MD, shared his perspective with Cardiovascular Business. 

Nee Khoo, MBChB, director of the echocardiography lab at Canada's Stollery Children’s Hospital, explains the rapid adoption of pediatric 3D transesophageal echo.

B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more.